NCT02940639View on ClinicalTrials.gov

Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy

CompletedOBSERVATIONAL
Enrollment

499

Participants

Timeline

Start Date

October 27, 2016

Primary Completion Date

June 3, 2025

Study Completion Date

June 3, 2025

Conditions
Renal Cell Carcinoma
Trial Locations (1)

07743

Local Institution - 0001, Jena

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02940639 - Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy | Biotech Hunter | Biotech Hunter